Bill Caragol, CFO of Mainz BioMed, was recently a guest on Benzinga's All-Access.
Mainz BioMed, maker of clinical laboratory tests, is committed to saving lives and reducing healthcare costs through early disease detection and prevention. For cancer and chronic conditions, patients can now live longer, healthier lives thanks to advances in diagnostic technology.
Mr. Caragol shared exciting info about Mainz Bio's early DETECT 2 study set to be completed in Q4 2025.
